A Win For Hepion Pharmaceuticals, Inc.

Hepion Pharmaceuticals, Inc. (HEPA:NASDAQ) jumped higher at $0.62, representing a gain of 35.4%. On Wed, Jan 11, 2023, HEPA:NASDAQ hit a New 2-Week High of $0.62. The stock appeared on our News Catalysts scanner on Tue, Jan 10, 2023 at 05:02 PM in the 'MERGER' category. From Wed, Dec 28, 2022, the stock recorded 55.56% Up Days and 70.00% Green Days

About Hepion Pharmaceuticals, Inc. (HEPA:NASDAQ)

ContraVir Pharmaceuticals Inc is a United States-based biopharmaceutical company engaged in the development of targeted pharmaceutical therapies for liver disease. The company focuses on developing two novel oral compounds to treat HBV infection. CRV431 is a cyclophilin inhibitor that targets specific isomerases that play an important role in protein folding in health and in disease. TXL is a nucleotide pro-drug of tenofovir that inhibits hepatitis B viral replication and targets the liver, the reservoir for the hepatitis B virus.